Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

Krka increases half-year sales by 6.7% and confirms annual forecast

Krka reports H1 2026 sales growth of 6.7% to €1,113.8 million and an EBITDA margin of 31.9% (H1 2025: 28.9%). EBIT rose 20% to €309 million with a margin of 27.6%, and net profit climbed to €260 million (+5%). Five of six regions recorded growth; Eastern Europe remains the largest region with €405.2 million (+9%). The company confirms its 2026 targets: around €2,144 million in sales and a net profit of approximately €405 million. » More on de.investing.com
Krka posts record revenue and operating profit in Q1 2026

Krka reports record revenue of €566 million in Q1 2026 (+8%) and an operating profit of €152 million (+24%), with an EBITDA margin of 31%—one of the highest levels in the company’s history. Net profit fell to €121 million (−21% versus Q1 2025) due to a strong year‑ago comparison. Management highlights growth from product-portfolio expansion, strong cash flows and a proposed quarterly dividend of €9.1 per share; risks remain currency fluctuations, supply-chain issues and competitive pressure. » More on de.investing.com
Krka posts over €2 billion in revenue for first time after strong Q4 2026

The Krka Group reported 2026 revenue of €2.041 billion, up 7% year-on-year, marking the first time in the company’s history it exceeded €2 billion. Net profit rose 13% to €401 million, EBITDA was €560 million (EBITDA margin 27.4%). In 2025 Krka launched seventeen new products, is focusing on chronic diseases and expanding in heart failure and obesity, and plans joint ventures in China and India. For 2026 the company forecasts revenue of €2.144 billion and plans to invest €140 million; the share price reacted with a 1.04% increase. » More on de.investing.com
Krka achieves annual revenue above €2 billion for first time after strong quarter

The Krka Group reports revenue of €2.041 billion (+7%) and net profit of €401 million (+13%) for the 2026 fiscal year, with earnings per share of €13.14. EBITDA amounted to €560 million with a margin of 27.4%. The share rose 2.36% to €954. For 2026, Krka expects revenue of €2.144 billion (+5%) and plans investments of €140 million for further expansion. » More on de.investing.com
Krka raises 2025 net profit forecast and cuts capex plan

After strong nine-month results, Krka raised its 2025 net profit forecast from €365 million to around €383 million, while keeping its revenue forecast unchanged. At the same time, the company reduced planned capital expenditures for 2025 from €150 million to about €95 million. In the first nine months, revenue rose to €1.534 billion (+6.9%) and net profit to €323 million (+15.1%); Krka attributes the growth in part to ruble appreciation, an improved product mix and economies of scale. For 2026, Krka expects revenue of around €2.132 billion and net profit of about €405 million, and plans higher capex of €140 million to modernize capacities. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Krka d.d. has already paid €9.10 in dividends. The last payout was in July.

Financials

In the last quarter, Krka d.d. had revenue of €554.74m and net profit of €139.61m

(EUR)	June 2026	YoY
Revenue	554.74m	5.38%
Gross profit	340.98m	12.55%
Net profit	139.61m	49.05%
EBITDA	180.66m	26.21%

Fundamentals

Metric	Value
Market capitalization	€7.6bn
Number of shares	30.28m
52-week high/low	€272.38 - €183.86
Dividend yield	3.61%
Dividends TTM	€9.10
Beta	0.46
P/E ratio	18.57
PEG ratio	2.10
P/B ratio	2.91
P/S ratio	3.59

Company profile

Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. Its prescription pharmaceuticals include medicines for the treatment of cardiovascular diseases; the gastrointestinal tract; central nervous system; pain relief; anti-infectives; blood and blood-forming organs; urological; diabetes; and oncology. The company also provides non-prescription products, such as products for oral cavity and pharynx; cough and cold products; analgesics; nasal products; vitamin and mineral products; products for enhancing cerebral and peripheral circulation; products for enhancing digestive tract and digestion; health care products; and others. In addition, it offers animal health products comprising antiinfectives, antiparasitics, and other products for farm and companion animals. Further, the company provides health resort and tourist services. Krka, d. d. was founded in 1954 and is headquartered in Novo Mesto, Slovenia.